Celgene Korea has elected Ham Tae-jin as its new CEO, the company said Tuesday.
“Korea is one of the most important countries for Celgene, acknowledged as the growth engine for Celgene Korea’s business with its excellent research infrastructure, researchers, and world-class R&D environment,” Ham said. “As such, I feel very honored to serve as the CEO of Celgene Korea.”
Ham received his bachelors and masters from Pusan National University, College of Pharmacy and received his MBA from the Wharton School of the University of Pennsylvania. He had worked at Eli Lilly and Co. as the general manager of Malaysia, Singapore, and Brunei. Ham moved to Celgene in 2015 to act as the Asian regional director of marketing and strategy, the company said.
The new CEO said that Celgene is currently developing a robust portfolio and pipeline in various diseases that have high medical demand such as blood cancers, solid cancers, and immune-related diseases. The company is currently supplying multiple myeloma treatments Revlimid and Pomalyst, myelodysplastic syndrome treatment Vidaza, and metastatic pancreatic cancer treatment Abraxane.
“Celgene will work to improve the lives of Korean patients based on its innovative treatments,” Ham added.